Fuchs Endothelial Corneal DystrophyNCT06966167
Comparison of Outcomes Between Femtosecond Laser-Assisted and Conventional Phacoemulsification in Fuchs Endothelial Corneal Dystrophy Patients With Cataracts
An observational study of Fuchs Endothelial Corneal Dystrophy and Cataract, run by Eye & ENT Hospital of Fudan University at 1 site in China.
Trial summary
The goal of this observational study is to compare the mid- to long-term efficacy of femtosecond laser-assisted cataract surgery (FLACS) and conventional phacoemulsification surgery (CPS) in patients with moderate to severe Fuchs' endothelial corneal dystrophy (FECD) complicated by cataracts. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Fuchs Endothelial Corneal Dystrophy, Cataract
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2025to Jan 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants aged 40 years or older, diagnosed with moderate to severe Fuchs endothelial corneal dystrophy (endothelial cell density < 1500 cells/mm²), and presenting with visually significant cataract.
Who may be able to join
- Patients scheduled for cataract surgery
- Age ≥40 years
- Diagnosed with moderate to severe FECD (endothelial cell density <1500 cells/mm²)
Who cannot join
- History of prior intraocular surgery
- Presence of ocular conditions other than FECD and cataracts (e.g., severe dry eye, corneal scarring, keratoconus, uveitis, uncontrolled glaucoma, vitreoretinal disease)
- Requirement for additional intraocular procedures during the study period (excluding Nd:YAG posterior capsulotomy)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Eye and ENT hospital of Fudan University
Shanghai, Shanghai Municipality, 200000
15088920668, 1532483480@qq.com
About this study
The goal of this observational study is to compare the mid- to long-term efficacy of femtosecond laser-assisted cataract surgery (FLACS) and conventional phacoemulsification surgery (CPS) in patients with moderate to severe Fuchs' endothelial corneal dystrophy (FECD) complicated by cataracts.
The main questions it aims to answer are:
Read more
Does FLACS lead to better preservation of corneal endothelial cells compared to CPS in patients with moderate to severe FECD? How do visual outcomes and corneal transparency compare between FLACS and CPS in this patient population?
Comparison Group:
Researchers will compare patients undergoing FLACS with those undergoing CPS to evaluate differences in endothelial cell loss, corneal thickness, visual acuity, and corneal transparency.
Participants:
Adults aged 40 years and older diagnosed with moderate to severe FECD (endothelial cell density <1500 cells/mm²).
Patients scheduled for cataract surgery at participating centers.
Participants will undergo:
Preoperative evaluations, including visual acuity tests, corneal endothelial cell density assessment (central and five peripheral zones), corneal thickness, and corneal densitometry.
Surgical intervention with either FLACS or CPS. Postoperative follow-ups at 1 day, 3 days, 1 week, 1 month, 3 months, 6 months, 1 year, and 2 years, including assessments of endothelial cell density, visual acuity, and corneal thickness.
This study aims to provide evidence-based recommendations for optimizing surgical strategies in high-risk patients with FECD and cataracts.
Read the detailed description
Fuchs' endothelial corneal dystrophy (FECD) is a progressive, bilateral corneal disorder characterized by endothelial cell loss, Descemet's membrane thickening, and corneal edema, leading to visual impairment. Patients with moderate to severe FECD are particularly vulnerable to corneal decompensation following cataract surgery due to their compromised endothelial function. As cataract surgery is a common necessity in this patient population, selecting an appropriate surgical technique that minimizes endothelial cell damage is crucial to ensuring optimal postoperative outcomes.
This observational, prospective, multi-center controlled study aims to compare the mid- to long-term efficacy and safety of femtosecond laser-assisted cataract surgery (FLACS) versus conventional phacoemulsification surgery (CPS) in patients with moderate to severe FECD undergoing cataract extraction. The study seeks to determine which technique better preserves corneal endothelial integrity and maintains visual function, providing valuable insights into surgical decision-making for this high-risk patient population.
Study Objectives The primary objective of this study is to evaluate the differences in corneal endothelial cell density (ECD) loss and corneal thickness changes between FLACS and CPS in patients with moderate to severe FECD undergoing cataract surgery.
The secondary objectives include:
Assessing differences in postoperative visual acuity, including uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA).
Comparing corneal densitometry and transparency changes between the two surgical techniques.
Evaluating postoperative corneal edema and potential complications related to endothelial decompensation.
Study Design Type: Prospective, observational, multi-center, controlled study Study Sites: Three ophthalmology centers with similar surgical and imaging equipment Participants: 120 eyes from 120 patients (FLACS group: 80 eyes; CPS group: 40 eyes)
Grouping: Patients will be assigned to either FLACS or CPS based on clinical indications rather than randomization. Subgroup analyses will be conducted based on:
Age (>70 years vs. ≤70 years) Preoperative endothelial cell density (<1000 cells/mm² vs. ≥1000 cells/mm²) Cataract nuclear grading (>grade 3 vs. ≤grade 3) Eligibility Criteria
Inclusion Criteria:
Patients scheduled for cataract surgery Age ≥40 years Diagnosed with moderate to severe FECD (endothelial cell density <1500 cells/mm²)
Exclusion Criteria:
History of prior intraocular surgery Presence of ocular conditions other than FECD and cataracts (e.g., severe dry eye, corneal scarring, keratoconus, uveitis, uncontrolled glaucoma, vitreoretinal disease) Requirement for additional intraocular procedures during the study period (excluding Nd:YAG posterior capsulotomy)
Discontinuation Criteria:
Failure to complete scheduled follow-up visits Serious adverse events (e.g., vision-threatening endophthalmitis) Participant withdrawal from the study Interventions \& Assessments
Preoperative Evaluation:
Comprehensive ophthalmic examination, including visual acuity testing (UDVA, CDVA), intraocular pressure (IOP), and refraction Biometric assessment using IOLMaster Corneal endothelial cell density measurement using specular microscopy and confocal microscopy (central, superior, inferior, nasal, and temporal zones) Corneal pachymetry and densitometry evaluation using Pentacam
Surgical Interventions:
FLACS Group: Patients will undergo femtosecond laser-assisted cataract surgery, which includes laser-assisted corneal incisions, capsulotomy, and lens fragmentation, followed by phacoemulsification.
CPS Group: Patients will undergo conventional phacoemulsification with manual capsulorhexis and lens nucleus fragmentation using ultrasound energy.
Postoperative Follow-Up Schedule:
Patients will be followed up at 1 day, 3 days, 1 week, 1 month, 3 months, 6 months, 1 year, and 2 years postoperatively. At each follow-up visit, the following assessments will be performed:
Visual acuity (UDVA, CDVA) Intraocular pressure measurement Corneal endothelial assessment using specular and confocal microscopy Corneal pachymetry and densitometry using Pentacam Outcome Measures
Primary Outcomes:
Change in central corneal endothelial cell density (ECD) from baseline to postoperative time points Change in corneal thickness from baseline to postoperative time points
Secondary Outcomes:
Change in corneal densitometry (central, superior, inferior, nasal, temporal zones) Postoperative visual acuity outcomes (UDVA, CDVA) Rate of corneal edema and decompensation Incidence of surgical complications (e.g., intraoperative endothelial damage, postoperative corneal haze) Statistical Analysis Continuous variables will be expressed as mean ± standard deviation (SD) and analyzed using t-tests or ANOVA.
Categorical variables will be analyzed using Chi-square tests. Non-normally distributed data will be evaluated using the Mann-Whitney U test. Longitudinal changes will be assessed using repeated-measures ANOVA or Friedman's test.
Pearson correlation analysis will be used to evaluate relationships between variables.
A p-value < 0.05 will be considered statistically significant.
Ethical Considerations This study will be conducted in compliance with the Declaration of Helsinki and national ethical guidelines. Informed consent will be obtained from all participants prior to enrollment. Patient confidentiality will be maintained through anonymized data collection and storage. The study protocol has been reviewed and approved by the institutional ethics committee.
Significance of the Study This study will provide critical evidence on the optimal surgical approach for cataract patients with FECD, guiding clinicians in making evidence-based surgical decisions to improve visual outcomes and reduce endothelial cell loss in this vulnerable population. It may also contribute to refining surgical techniques and identifying best practices for preserving corneal endothelial health during cataract surgery in patients with pre-existing endothelial dysfunction.
- Conditions
- Fuchs Endothelial Corneal Dystrophy, Cataract
- Keywords
- Fuchs Endothelial Corneal Dystrophy, Cataract, Femtosecond Laser-Assisted Cataract Surgery, Conventional Phacoemulsification Surgery
- Medical subject headings
- Fuchs' Endothelial Dystrophy, Cataract
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| conventional phacoemulsification surgery (CPS) | Not described | |
| femtosecond laser-assisted cataract surgery (FLACS) | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in central corneal endothelial cell density (ECD) from baseline to postoperative time points
Measured: From enrollment to the end of treatment at 2years
Change in corneal thickness from baseline to postoperative time points
Measured: From enrollment to the end of treatment at 2years
Secondary outcomes (2)
Change in corneal densitometry (central, superior, inferior, nasal, temporal zones)
Measured: From enrollment to the end of treatment at 2years
Postoperative visual acuity outcomes (UDVA, CDVA)
Measured: From enrollment to the end of treatment at 2years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2025
- Study start1 Jan 2025
- Primary completionJan 2030 (estimated)
- Study completionJan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Fuchs Endothelial Corneal DystrophyStudies of the same condition, open and under way.
- More trials run by Eye & ENT Hospital of Fudan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eye & ENT Hospital of Fudan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jin Yang, Eye & ENT Hospital of Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06966167
- Sponsor's protocol ID
- Fuchs FLACS vs CPS
- Status last verified
- Jun 2025
- First submitted
- 3 May 2025
- Last updated
- 17 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Lupardi E, Moramarco A, Cassini F, Febbraro S, Savini G, Fontana L. Corneal densitometry measurements comparison between anterior segment OCT and scheimpflug imaging. Int Ophthalmol. 2024 Sep 25;44(1):392. doi: 10.1007/s10792-024-03309-0.
PubMed 39320570Aiello F, Gallo Afflitto G, Ceccarelli F, Cesareo M, Nucci C. Global Prevalence of Fuchs Endothelial Corneal Dystrophy (FECD) in Adult Population: A Systematic Review and Meta-Analysis. J Ophthalmol. 2022 Apr 14;2022:3091695. doi: 10.1155/2022/3091695. eCollection 2022.
PubMed 35462618Ali M, Cho K, Srikumaran D. Fuchs Dystrophy and Cataract: Diagnosis, Evaluation and Treatment. Ophthalmol Ther. 2023 Apr;12(2):691-704. doi: 10.1007/s40123-022-00637-1. Epub 2023 Jan 13.
PubMed 36637659Bourne WM, Nelson LR, Hodge DO. Central corneal endothelial cell changes over a ten-year period. Invest Ophthalmol Vis Sci. 1997 Mar;38(3):779-82.
PubMed 9071233
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Outcomes Between Femtosecond Laser-Assisted and Conventional Phacoemulsification in Fuchs Endothelial Corneal Dystrophy Patients With Cataracts
- ClinicalTrials.gov ID
- NCT06966167
- Acronym / sponsor ID
- Fuchs FLACS vs CPS
- Conditions
- Fuchs Endothelial Corneal Dystrophy, Cataract
- Keywords
- Fuchs Endothelial Corneal Dystrophy, Cataract, Femtosecond Laser-Assisted Cataract Surgery, Conventional Phacoemulsification Surgery
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Eye & ENT Hospital of Fudan UniversityUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- Jan 2030 (estimated)
- Study completion
- Jan 2030 (estimated)
- First posted
- 11 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to compare the mid- to long-term efficacy of femtosecond laser-assisted cataract surgery (FLACS) and conventional phacoemulsification surgery (CPS) in patients with moderate to severe Fuchs' endothelial corneal dystrophy (FECD) complicated by cataracts.
The main questions it aims to answer are:
Does FLACS lead to better preservation of corneal endothelial cells compared to CPS in patients with moderate to severe FECD? How do visual outcomes and corneal transparency compare between FLACS and CPS in this patient population?
Comparison Group:
Researchers will compare patients undergoing FLACS with those undergoing CPS to evaluate differences in endothelial cell loss, corneal thickness, visual acuity, and corneal transparency.
Participants:
Adults aged 40 years and older diagnosed with moderate to severe FECD (endothelial cell density <1500 cells/mm²).
Patients scheduled for cataract surgery at participating centers.
Participants will undergo:
Preoperative evaluations, including visual acuity tests, corneal endothelial cell density assessment (central and five peripheral zones), corneal thickness, and corneal densitometry.
Surgical intervention with either FLACS or CPS. Postoperative follow-ups at 1 day, 3 days, 1 week, 1 month, 3 months, 6 months, 1 year, and 2 years, including assessments of endothelial cell density, visual acuity, and corneal thickness.
This study aims to provide evidence-based recommendations for optimizing surgical strategies in high-risk patients with FECD and cataracts.
Detailed description
Fuchs' endothelial corneal dystrophy (FECD) is a progressive, bilateral corneal disorder characterized by endothelial cell loss, Descemet's membrane thickening, and corneal edema, leading to visual impairment. Patients with moderate to severe FECD are particularly vulnerable to corneal decompensation following cataract surgery due to their compromised endothelial function. As cataract surgery is a common necessity in this patient population, selecting an appropriate surgical technique that minimizes endothelial cell damage is crucial to ensuring optimal postoperative outcomes.
This observational, prospective, multi-center controlled study aims to compare the mid- to long-term efficacy and safety of femtosecond laser-assisted cataract surgery (FLACS) versus conventional phacoemulsification surgery (CPS) in patients with moderate to severe FECD undergoing cataract extraction. The study seeks to determine which technique better preserves corneal endothelial integrity and maintains visual function, providing valuable insights into surgical decision-making for this high-risk patient population.
Study Objectives The primary objective of this study is to evaluate the differences in corneal endothelial cell density (ECD) loss and corneal thickness changes between FLACS and CPS in patients with moderate to severe FECD undergoing cataract surgery.
The secondary objectives include:
Assessing differences in postoperative visual acuity, including uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA).
Comparing corneal densitometry and transparency changes between the two surgical techniques.
Evaluating postoperative corneal edema and potential complications related to endothelial decompensation.
Study Design Type: Prospective, observational, multi-center, controlled study Study Sites: Three ophthalmology centers with similar surgical and imaging equipment Participants: 120 eyes from 120 patients (FLACS group: 80 eyes; CPS group: 40 eyes)
Grouping: Patients will be assigned to either FLACS or CPS based on clinical indications rather than randomization. Subgroup analyses will be conducted based on:
Age (>70 years vs. ≤70 years) Preoperative endothelial cell density (<1000 cells/mm² vs. ≥1000 cells/mm²) Cataract nuclear grading (>grade 3 vs. ≤grade 3) Eligibility Criteria
Inclusion Criteria:
Patients scheduled for cataract surgery Age ≥40 years Diagnosed with moderate to severe FECD (endothelial cell density <1500 cells/mm²)
Exclusion Criteria:
History of prior intraocular surgery Presence of ocular conditions other than FECD and cataracts (e.g., severe dry eye, corneal scarring, keratoconus, uveitis, uncontrolled glaucoma, vitreoretinal disease) Requirement for additional intraocular procedures during the study period (excluding Nd:YAG posterior capsulotomy)
Discontinuation Criteria:
Failure to complete scheduled follow-up visits Serious adverse events (e.g., vision-threatening endophthalmitis) Participant withdrawal from the study Interventions \& Assessments
Preoperative Evaluation:
Comprehensive ophthalmic examination, including visual acuity testing (UDVA, CDVA), intraocular pressure (IOP), and refraction Biometric assessment using IOLMaster Corneal endothelial cell density measurement using specular microscopy and confocal microscopy (central, superior, inferior, nasal, and temporal zones) Corneal pachymetry and densitometry evaluation using Pentacam
Surgical Interventions:
FLACS Group: Patients will undergo femtosecond laser-assisted cataract surgery, which includes laser-assisted corneal incisions, capsulotomy, and lens fragmentation, followed by phacoemulsification.
CPS Group: Patients will undergo conventional phacoemulsification with manual capsulorhexis and lens nucleus fragmentation using ultrasound energy.
Postoperative Follow-Up Schedule:
Patients will be followed up at 1 day, 3 days, 1 week, 1 month, 3 months, 6 months, 1 year, and 2 years postoperatively. At each follow-up visit, the following assessments will be performed:
Visual acuity (UDVA, CDVA) Intraocular pressure measurement Corneal endothelial assessment using specular and confocal microscopy Corneal pachymetry and densitometry using Pentacam Outcome Measures
Primary Outcomes:
Change in central corneal endothelial cell density (ECD) from baseline to postoperative time points Change in corneal thickness from baseline to postoperative time points
Secondary Outcomes:
Change in corneal densitometry (central, superior, inferior, nasal, temporal zones) Postoperative visual acuity outcomes (UDVA, CDVA) Rate of corneal edema and decompensation Incidence of surgical complications (e.g., intraoperative endothelial damage, postoperative corneal haze) Statistical Analysis Continuous variables will be expressed as mean ± standard deviation (SD) and analyzed using t-tests or ANOVA.
Categorical variables will be analyzed using Chi-square tests. Non-normally distributed data will be evaluated using the Mann-Whitney U test. Longitudinal changes will be assessed using repeated-measures ANOVA or Friedman's test.
Pearson correlation analysis will be used to evaluate relationships between variables.
A p-value < 0.05 will be considered statistically significant.
Ethical Considerations This study will be conducted in compliance with the Declaration of Helsinki and national ethical guidelines. Informed consent will be obtained from all participants prior to enrollment. Patient confidentiality will be maintained through anonymized data collection and storage. The study protocol has been reviewed and approved by the institutional ethics committee.
Significance of the Study This study will provide critical evidence on the optimal surgical approach for cataract patients with FECD, guiding clinicians in making evidence-based surgical decisions to improve visual outcomes and reduce endothelial cell loss in this vulnerable population. It may also contribute to refining surgical techniques and identifying best practices for preserving corneal endothelial health during cataract surgery in patients with pre-existing endothelial dysfunction.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| conventional phacoemulsification surgery (CPS) | – | – |
| femtosecond laser-assisted cataract surgery (FLACS) | – | – |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants aged 40 years or older, diagnosed with moderate to severe Fuchs endothelial corneal dystrophy (endothelial cell density < 1500 cells/mm²), and presenting with visually significant cataract.
Key inclusion criteria (3 listed)
- Patients scheduled for cataract surgery
- Age ≥40 years
- Diagnosed with moderate to severe FECD (endothelial cell density <1500 cells/mm²)
Key exclusion criteria (3 listed)
- History of prior intraocular surgery
- Presence of ocular conditions other than FECD and cataracts (e.g., severe dry eye, corneal scarring, keratoconus, uveitis, uncontrolled glaucoma, vitreoretinal disease)
- Requirement for additional intraocular procedures during the study period (excluding Nd:YAG posterior capsulotomy)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in central corneal endothelial cell density (ECD) from baseline to postoperative time points
Time frame: From enrollment to the end of treatment at 2years
Change in corneal thickness from baseline to postoperative time points
Time frame: From enrollment to the end of treatment at 2years
2 secondary outcomes
Change in corneal densitometry (central, superior, inferior, nasal, temporal zones)
Time frame: From enrollment to the end of treatment at 2years
Postoperative visual acuity outcomes (UDVA, CDVA)
Time frame: From enrollment to the end of treatment at 2years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2025.
- Results publication: PubMed 39320570Lupardi E, Moramarco A, Cassini F, Febbraro S, Savini G, Fontana L. Corneal densitometry measurements comparison between anterior segment OCT and scheimpflug imaging. Int Ophthalmol. 2024 Sep 25;44(1):392. doi: 10.1007/s10792-024-03309-0.
- Results publication: PubMed 35462618Aiello F, Gallo Afflitto G, Ceccarelli F, Cesareo M, Nucci C. Global Prevalence of Fuchs Endothelial Corneal Dystrophy (FECD) in Adult Population: A Systematic Review and Meta-Analysis. J Ophthalmol. 2022 Apr 14;2022:3091695. doi: 10.1155/2022/3091695. eCollection 2022.
- Results publication: PubMed 36637659Ali M, Cho K, Srikumaran D. Fuchs Dystrophy and Cataract: Diagnosis, Evaluation and Treatment. Ophthalmol Ther. 2023 Apr;12(2):691-704. doi: 10.1007/s40123-022-00637-1. Epub 2023 Jan 13.
- Results publication: PubMed 9071233Bourne WM, Nelson LR, Hodge DO. Central corneal endothelial cell changes over a ten-year period. Invest Ophthalmol Vis Sci. 1997 Mar;38(3):779-82.
- Individual participant dataSharing planned: Undecided
Related trials for Fuchs Endothelial Corneal Dystrophy
Active, not recruitingPhase 3
Descemet Endothelial Thickness Comparison Trial II
Fuchs, Fuchs Dystrophy
RecruitingPhase 2
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Corneal Edema, Fuchs
RecruitingObservational study
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Keratoconus, Ectasia
RecruitingPhase 2
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
Fuchs Endothelial Corneal Dystrophy, Fuchs
Active, not recruiting
The Belgian Endothelial Surgical Transplant of the Cornea
Corneal Edema, Corneal Endothelial Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fuchs Endothelial Corneal Dystrophy and Cataract, run by Eye & ENT Hospital of Fudan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jin Yang (+86 021-64377134, jin_er76@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in central corneal endothelial cell density (ECD) from baseline to postoperative time points (time frame: From enrollment to the end of treatment at 2years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06966167, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2025.